Some Considerations When Designing ADaM Datasets
|
|
- Daniela Merritt
- 5 years ago
- Views:
Transcription
1 Some Considerations When Designing ADaM Datasets Italian CDISC UN Day - Milan 27 th October 2017 Antonio Valenti Principal Statistical Programmer CROS NT - Verona
2 Content Disclaimer All content included in this presentation is for informational purposes only. These are from personal notes taken during the attendance of the webinar in reference. Please refer to the original presentation and to the latest published standards documents for the most authoritative implementation information.
3 Reference CDISC Members Only Mini-Training Series Some Considerations When Designing ADaM Datasets Nate Freimark, Vice President -Clinical Programming and Date Standards, The Griesser Group CDISC Webinar 09MAR2017
4 Overview General concepts ADSL related tips &FAQ BDS related tips &FAQ OCCDS related tips &FAQ
5 General #1 Variables selection Just because a variable is defined in the ADaMIG does not mean it has to be created in an/all ADaM datasets: SITEID/SUBJID in all BDS datasets TM and DTM variables when time is missing Numeric variables not used in analysis (i.e. ARMN) Null variables (i.e. AVISIT/AVISITN) Variables from ADSL can be copied to other ADaM datasets without renaming to a new variable (i.e. AX01SDT in BDS = ADSL.TR01SDT) Variables coming from SDTM should be copied without changes, but bad SDTM should not necessarily translate to bad ADaM (i.e. TPT containing VISIT)
6 General #2 Date/time variables Respect suffix conventions (DT, TM, DTM, DTF, TMF, DY) Date/time variables should have associated study day variables. When date/time imputation are needed it is a good idea to keep the SDTM variable that contains the partial value Creating the DT, TM, and DTM triplicate just because it can be done is not necessary For a given SDTM DTC variable, if only hh and mm are collected, and ss are imputed in *DTM as 00, then it is not necessary to set *TMF to S. However if collected but are missing should be qualified in *TMF.
7 General #2 (example) Date/time Example 1 SDTM ADAM --DTC T12: T10:30 --DT --TM --DY :00: :30:00 16 Date/time Example 2 SDTM ADAM --DTC T12: T10:31:50 --DT --TM --TMF --DY :00:00 S :31:50 16
8 General #3 Visit/Time Point Variables AVISIT/AVISITN/ATPT/ATPN should be the timing variables that are in datasets VISIT/VISITNUM/--TPT/--TPTNUM should also be kept if the values/algorithms differ VISIT/VISITNUM have to come from SDTM and cannot be derived/changed in ADaM but bad SDTM should not necessarily translate to bad ADaM (TPT containing VISIT values) AVISIT last value within a window is not an ENDPOINT value unless you are outputting an extra record if true then DTYPE has to be present. If not then ANLzzFLshould be used AVISIT RESCREEN/UNSCHEDULED are not generally valid AVISIT values unless they are summarized on the table or defined in the SAP if not they should be null (or windowed)
9 General #3 (example) Visit/time point bad implementation AVISIT ATPT PARAM Day 1 12 h Heart rate (bpm) Day 1 12 h Baseline Baseline DIASTOLIC BLOOD PRESSURE Visit/time point good implementation AVISIT ATPT PARAM Day 1 12 h Heart rate (bpm) Baseline Diastolic Blood Pressure (mmhg)* uses XXSTRESU value
10 ADSL #1 Population Flags ITTFL do not created it, if is same as RANDFL and not defined in protocol/sap RANDFL why is it tied to being dosed? DISCFL this appears to be the inverse of COMPLFL (only one) NOMEDFL what is the purpose of a combination flag? (use the available flags) Some population flags in the efficacy analysis are too complicated. Can we generate these population flags by referring to each other? Circular logic is always a concern
11 ADSL #2 Treatment Variables ARM/ARMCD are not analysis variables do not have to be included in every dataset Use (TRTSEQP) There is no variable ARMGR1 in ADaM ARMN is not necessary ARM is required per the ADaMIG v1.1 for traceability, ACTARM is perm TRT01A do you check whether Actual differs from Planned or do you always create? Check order TRT01P vs TRT02P (TR01SDT/TR01EDT vs TR02SDT/TR02EDT). Check also TRTSEQP (order is reversed?)
12 ADSL #3 Treatment duration Duration AEXDURN I don t see why this is prefixed with A/Analysis EXDURN is sufficient xxxdur DUR in SDTM is ISO8601. Use ADaMIG v1.1 defined variables and xxxdurc (if needed) ADSL do you have any subjects with missing disposition records? it should be null in that case and not discontinued make sure metadata covers all scenarios
13 ADSL #4 Date Variables APxxSDT/APxxEDT are paired variables both or neither should be present There should not be more APxx variables then there are TRTxxP ADSL.TRTSDT/TRTEDT required ADSL.TR01SDT/TR01EDT not needed in a single period trial TRTSDT/TRTEDT based on RFX not RF (start of trt not the study) LSTVST (based on Last SV record in spec)? SV has no order unless VISITNUM is in the correct order VISITNUM (i.e. 99 for Unscheduled) Is there a reason you format dates as DATE9 instead of YYMMDD10? No right or wrong but you should be consistent across datasets
14 ADSL #5 Other Variables SEX per SDTM is M/F you cannot change any SDTM variable value in ADaM DEATHFL why not use SDTM variable DTHFL? DSTERM/DSDECOD may be one of several DS records renaming to useful concept is helpful HEIGHT should be HEIGHTBL or BLHEIGHT to indicate it is a baseline value (similar to label) Baseline variables should start or end with BL and not just B AGEU is required
15 Population flags BDS #1 all BDS have to have at least one population flag variable however not all ADSL population variables have to included in every ADaM dataset Can we add free text to the label of ANLzzFL or any variable with y, zz, xx? e.g: added text Analysis Flag zz Last for Dup. Records. Yes for y and zz but not for xx ADxx-xxxxxFL values of 1-4 are not allowed for an FL variable ADLB -no ANLzzFL variables are needed for analysis? (this is possible if there are no multiple nominal visit values and unscheduled values are not summarized) Is BLFL=Y always the value where ABLFL=Y?
16 BDS #2 Incorrect/Iffy Variables/Values AVALU is not a valid ADaM variable if unit is relevant it should be included in PARAM if not then just keep ORRESU/STRESU ADxx-AVALC is not left-justified for numeric values (nor does AVALC have to be populated for numeric parameters) ADDV -AVALC are these values actually analyzed/summarized? Is there a protocol deviation summary why was this ADaM created? Shouldn t ADDV be OCCDS in any case? ADPE -Summary is by AVISIT why are ABLFL/BASEC needed?
17 BDS #3 PARAM/PARAMCD/LBCAT ADLB -LBTEST/LBTESTCD generally are not sufficient for PARAM/PARAMCD in labs since there are the same TEST in CHEMISTRY and URINALYSISPARAM/PARAMCD have to uniquely identify -using PARCAT1 is not allowed GLUC cannot have two different PARCAT1 values Is it your standard or the sponsor s standard to capture LBCAT in PARAM instead of only the ones that are common in more than one LBCAT? Any value added in capturing on all PARAMCD? Only add U to the ones that are in more than one LBCAT can be enough
18 BDS #3 (Example) PARAM/PARAMCD/LBCAT Wrong definition PARAMCD PARAM PARCAT1 CA Urine Calcium URINALYSIS CA Blood Calcium CHEMISTRY RBC Blood Erythrocytes HAEMATOLOGY Correct definition CAU Urine Calcium URINALYSIS CA Calcium CHEMISTRY RBC Erythrocytes HAEMATOLOGY
19 BDS #4 Incorrect/Iffy Variables/Values (continue) ADLB -A lot of the PARAM appear to be CRIT values and should not be added parameters (e.galkgr15) -for the ones that look at multiple PARAM it makes sense but not so much for the ones that are within PARAM
20 BDS #4 (Example) PARAM/PARAMCD/LBCAT Bad definition PARAMCD AVAL AVALC ALK 20 ALKGR15 20 Y Good definition PARAMCD AVAL CRIT1 CRIT1FL ALK 20 ALK > 15 Y
21 BDS #5 BASE/BASETYPE ADLB -BASETYPE is not populated for all records within a PARAM ADLB/ADVS -Having BASE and not CHG seems odd what is the purpose? BASE should reference ABLFL and not AVISITN ADaMIG -BASE contains the value of AVAL copied from a record within the parameter on which ABLFL = Y (and BNRIND=ANRIND where ABLFL= Y ) AVALCATy/CRITy ADxx.AVALCAT1/AVALCAT2 -these can only be categorizations of AVAL only CRITy/MCRITy can be based on any variable CRITy has to be a constant value within PARAM if it varies then use AVALCATy (or MCRITyML)
22 BDS #5 (Example) AVALCATy/CRITy Bad definition AVAL AVALC CHG AVALCAT1* 90 High 20 GT 90 and CHG > High 10 Good definition AVAL AVALC CHG AVALCAT1 CRIT1* CRIT1FL* High GT 90 and CHG > 20 Y High
23 BDS #6 Timing Variables ENDPOINT BASELINE is not a correct AVISIT value this should be AVISIT=BASELINE with DTYPE=AVERAGE. Why are there AVISIT=ENDPOINT xxxx in any case it does not have that on the tables What does ATPT=ENDPOINT 0.5 H POST-DOSE mean? If these are supposed to identify the average value then DBTYPE should be used and not a changed ATPT value it is not a different visit/timepoint ADTC often included this. Value added?
24 BDS #7 DTYPE DTYPE=SUM or COMBINED is incorrect DTYPE is for records within a parameter and not totally derived parameters DTYPE=MAXIMUM (used to identify a maximum record) -this is incorrect usage of DTYPE -there is no indication that there is an added row with AVISIT="Maximum" -this should be identified with an ANLzzFL DTYPE=EOT is not correct it does not describe the derivation method (it could be LOV Last Observed Value) ADLB -LBMAXFL/LBMINFL/POSTHIFL/POSTLOFL (and all the rest of the flags) these should all be ANLzzFL (or AVISIT added rows) see section of the ADaMIG
25 BDS #7 (Example) Wrong AVISIT PARAMCD AVAL DBTYPE Week 1 DBP 80 Week 2 DBP 120 MAXIMUM POSTHIFL Y Use ANLxxFL Add AVISIT and Use DBTYPE AVISIT PARAMCD AVAL ANL01FL Week 1 DBP 80 Week 2 DBP 120 Y AVISIT PARAMCD AVAL DBTYPE Week 1 DBP 80 Week 2 DBP 120 Post-Baseline Maximum DBP 120 MAXIMUM
26 OCCDS #1 ADAE ADAE -Creating records with ANYAE=N and populating AETERM with None for subjects with no AEs is not allowed AEDUR is an SDTM variable that is character and ISO 8601 it cannot be changed to numeric in ADaM. Use ADURN (derived) Do not change SDTM variables as AEOUTR (SDTM.AE.AEOUT), AESEV should be SDTM.AESEV TRTEMFL -derivation may not be correct if time is imputed use caution in defining TRTEMFL ASTDT should be included even if ASTDTM is present. No a requirement just a suggestion
27 OCCDS #2 ADCM /ADMH ADCM -CMDOSU/CMDOSFRQ/CMROUTE changed from SDTM values this is not allowed ADMH ASTDT/AENDT do these add value? These appear to be mostly partial dates
28 Conclusion Thanks for your attention Questions?
Yes! The basic principles of ADaM are also best practice for our industry Yes! ADaM a standard with enforceable rules and recognized structures Yes!
1 Yes! The basic principles of ADaM are also best practice for our industry Yes! ADaM a standard with enforceable rules and recognized structures Yes! The ADaM documentation provides examples of many of
More informationPharmaSUG Paper DS06 Designing and Tuning ADaM Datasets. Songhui ZHU, K&L Consulting Services, Fort Washington, PA
PharmaSUG 2013 - Paper DS06 Designing and Tuning ADaM Datasets Songhui ZHU, K&L Consulting Services, Fort Washington, PA ABSTRACT The developers/authors of CDISC ADaM Model and ADaM IG made enormous effort
More informationPharmaSUG Paper DS24
PharmaSUG 2017 - Paper DS24 ADQRS: Basic Principles for Building Questionnaire, Rating and Scale Datasets Nancy Brucken, inventiv Health, Ann Arbor, MI Karin LaPann, Shire, Lexington, MA ABSTRACT Questionnaires,
More informationADaM Implementation Guide Prepared by the CDISC ADaM Team
1 2 3 ADaM Implementation Guide Prepared by the CDISC ADaM Team 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Revision History Notes to Readers Date Version Summary of Changes May 30, 2008 1.0 Draft
More informationDCDISC Users Group. Nate Freimark Omnicare Clinical Research Presented on
DCDISC Users Group Nate Freimark Omnicare Clinical Research Presented on 2011-05-12 1 Disclaimer The opinions provided are solely those of the author and not those of the ADaM team or Omnicare Clinical
More informationIntroduction to ADaM and What s new in ADaM
Introduction to ADaM and What s new in ADaM Italian CDISC UN Day - Milan 27 th October 2017 Silvia Faini Principal Statistical Programmer CROS NT - Verona ADaM Purpose Why are standards needed in analysis
More informationFrom SAP to BDS: The Nuts and Bolts Nancy Brucken, i3 Statprobe, Ann Arbor, MI Paul Slagle, United BioSource Corp., Ann Arbor, MI
PharmaSUG2011 - Paper HW05 From SAP to BDS: The Nuts and Bolts Nancy Brucken, i3 Statprobe, Ann Arbor, MI Paul Slagle, United BioSource Corp., Ann Arbor, MI ABSTRACT You've just read through the protocol,
More informationDeriving Rows in CDISC ADaM BDS Datasets
ABSTRACT PharmaSUG 2017 Paper DS22 Deriving Rows in CDISC ADaM BDS Datasets Sandra Minjoe, Accenture Accelerated R&D Services The ADaM Basic Data Structure (BDS) can be used for many analysis needs, including
More informationLeveraging ADaM Principles to Make Analysis Database and Table Programming More Efficient Andrew L Hulme, PPD, Kansas City, MO
PharmaSUG 2015 - Paper PO13 Leveraging ADaM Principles to Make Analysis Database and Table Programming More Efficient Andrew L Hulme, PPD, Kansas City, MO ABSTRACT The purpose of the CDISC Analysis Data
More informationRiepilogo e Spazio Q&A
Riepilogo e Spazio Q&A CDISC Italian User Network Day 27 Ottobre 2017 Angelo Tinazzi (Cytel) - Silvia Faini (CROS NT) E3C members 2 Agenda ADaM key list Bad & Good ADaM...More... Spazio Q&A ADaM Key List
More informationADaM IG v1.1 & ADaM OCCDS v1.0. Dr. Silke Hochstaedter
ADaM IG v1.1 & ADaM OCCDS v1.0 Dr. Silke Hochstaedter 1 Agenda What s new in Analysis Data Model Implementation Guide Version 1.1 The new ADaM Structure for Occurrence Data (OCCDS) Version 1.0 Q&A ADaM
More informationCreating an ADaM Data Set for Correlation Analyses
PharmaSUG 2018 - Paper DS-17 ABSTRACT Creating an ADaM Data Set for Correlation Analyses Chad Melson, Experis Clinical, Cincinnati, OH The purpose of a correlation analysis is to evaluate relationships
More informationIntroduction to ADaM standards
Introduction to ADaM standards Elke Sennewald, Director Biostatistics EU/AP, 06 March 2009 1 Outline ADaM Version 2.0 / 2.1 General Considerations ADaM draft Version 2.1 ADaMIG draft Version 1.0 ADaM Variables
More informationProgramming checks: Reviewing the overall quality of the deliverables without parallel programming
PharmaSUG 2016 Paper IB04 Programming checks: Reviewing the overall quality of the deliverables without parallel programming Shailendra Phadke, Baxalta US Inc., Cambridge MA Veronika Csom, Baxalta US Inc.,
More informationPharmaSUG Paper DS-24. Family of PARAM***: PARAM, PARAMCD, PARAMN, PARCATy(N), PARAMTYP
PharmaSUG 2018 - Paper DS-24 Family of PARAM***: PARAM, PARAMCD, PARAMN, PARCATy(N), PARAMTYP Kamlesh Patel, Rang Technologies Inc, New Jersey Jigar Patel, Rang Technologies Inc, New Jersey Dilip Patel,
More informationAn Efficient Solution to Efficacy ADaM Design and Implementation
PharmaSUG 2017 - Paper AD05 An Efficient Solution to Efficacy ADaM Design and Implementation Chengxin Li, Pfizer Consumer Healthcare, Madison, NJ, USA Zhongwei Zhou, Pfizer Consumer Healthcare, Madison,
More informationAvoiding Sinkholes: Common Mistakes During ADaM Data Set Implementation
ABSTRACT Avoiding Sinkholes: Common Mistakes During ADaM Data Set Implementation Richann Watson, Experis, Batavia, OH Karl Miller, inventiv Health, Lincoln, NE The ADaM Implementation Guide was created
More informationAnalysis Data Model Implementation Guide Version 1.1 (Draft) Prepared by the CDISC Analysis Data Model Team
Analysis Data Model Implementation Guide Version 1.1 (Draft) Prepared by the CDISC Analysis Data Model Team Notes to Readers This Implementation Guide is version 1.1 and corresponds to Version 2.1 of the
More informationHow to write ADaM specifications like a ninja.
Poster PP06 How to write ADaM specifications like a ninja. Caroline Francis, Independent SAS & Standards Consultant, Torrevieja, Spain ABSTRACT To produce analysis datasets from CDISC Study Data Tabulation
More informationIt s All About Getting the Source and Codelist Implementation Right for ADaM Define.xml v2.0
PharmaSUG 2018 - Paper SS-15 It s All About Getting the Source and Codelist Implementation Right for ADaM Define.xml v2.0 ABSTRACT Supriya Davuluri, PPD, LLC, Morrisville, NC There are some obvious challenges
More informationTraceability in the ADaM Standard Ed Lombardi, SynteractHCR, Inc., Carlsbad, CA
ABSTRACT PharmaSUG 2013 - Paper PO13 Traceability in the ADaM Standard Ed Lombardi, SynteractHCR, Inc., Carlsbad, CA Traceability is one of the fundamentals of the ADaM Standard. However, there is not
More informationADaM Compliance Starts with ADaM Specifications
PharmaSUG 2017 - Paper DS16 ADaM Compliance Starts with ADaM Specifications Trevor Mankus, Kent Letourneau, PRA Health Sciences ABSTRACT As of December 17th, 2016, the FDA and PMDA require that all new
More informationNCI/CDISC or User Specified CT
NCI/CDISC or User Specified CT Q: When to specify CT? CT should be provided for every variable with a finite set of valid values (e.g., the variable AESEV in ADAE can have the values MILD, MODERATE or
More informationClarifications About ADaM Implementation Provided in ADaMIG Version 1.1
PharmaSUG 2017 - Paper DS18 Clarifications About ADaM Implementation Provided in ADaMIG Version 1.1 John Troxell, Accenture ABSTRACT Since the publication of version 1.0 of the CDISC (Clinical Data Interchange
More informationADaM Reviewer s Guide Interpretation and Implementation
Paper CD13 ADaM Reviewer s Guide Interpretation and Implementation Steve Griffiths, GlaxoSmithKline, Stockley Park, UK ABSTRACT Throughout the course of a study, teams will make a lot of decisions about
More informationTraceability: Some Thoughts and Examples for ADaM Needs
PharmaSUG 2018 - Paper DS-01 Traceability: Some Thoughts and Examples for ADaM Needs Sandra Minjoe, PRA Health Sciences; Wayne Zhong, Accretion Softworks; Quan (Jenny) Zhou, Eli Lilly and Company; Kent
More informationHands-On ADaM ADAE Development Sandra Minjoe, Accenture Life Sciences, Wayne, Pennsylvania
PharmaSUG 2013 - Paper HT03 Hands-On ADaM ADAE Development Sandra Minjoe, Accenture Life Sciences, Wayne, Pennsylvania ABSTRACT The Analysis Data Model (ADaM) Data Structure for Adverse Event Analysis
More informationAnalysis Data Model (ADaM) Data Structure for Adverse Event Analysis
Analysis Data Model (ADaM) Data Structure for Adverse Event Analysis Prepared by the CDISC Analysis Data Model Team Notes to Readers This Analysis model uses the principles, structure and standards described
More informationHands-On ADaM ADAE Development Sandra Minjoe, Accenture Life Sciences, Wayne, Pennsylvania Kim Minkalis, Accenture Life Sciences, Wayne, Pennsylvania
PharmaSUG 2014 - Paper HT03 Hands-On ADaM ADAE Development Sandra Minjoe, Accenture Life Sciences, Wayne, Pennsylvania Kim Minkalis, Accenture Life Sciences, Wayne, Pennsylvania ABSTRACT The Analysis Data
More informationDealing with changing versions of SDTM and Controlled Terminology (CT)
CDISC UK Network Breakout session Notes 07/06/16 Afternoon Session 1: Dealing with changing versions of SDTM and Controlled Terminology (CT) How do people manage this? Is this managed via a sponsor Standards
More informationMetadata and ADaM.
Metadata and ADaM 1 Disclaimer Any views or opinions presented in this presentation are solely those of the author and do not necessarily represent those of the company. 2 Agenda Introduction of ADaM Metadata
More informationADaM Implementation Guide Status Update
ADaM Implementation Guide Status Update John K. Troxell John Troxell Consulting LLC Bridgewater, NJ jktroxell@gmail.com June 17, 2013 Current CDISC ADaM Documents 2009 Analysis Data Model (ADaM), Version
More informationWhat is the ADAM OTHER Class of Datasets, and When Should it be Used? John Troxell, Data Standards Consulting
Accenture Accelerated R&D Services Rethink Reshape Restructure for better patient outcomes What is the ADAM OTHER Class of Datasets, and When Should it be Used? John Troxell, Data Standards Consulting
More informationThe Implementation of Display Auto-Generation with Analysis Results Metadata Driven Method
PharmaSUG 2015 - Paper AD01 The Implementation of Display Auto-Generation with Analysis Results Metadata Driven Method Chengxin Li, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA ABSTRACT
More informationApplying ADaM Principles in Developing a Response Analysis Dataset
PharmaSUG2010 Paper CD03 Applying ADaM Principles in Developing a Response Analysis Dataset Mei Dey, Merck & Co., Inc Lisa Pyle, Merck & Co., Inc ABSTRACT The Clinical Data Interchange Standards Consortium
More informationTraceability Look for the source of your analysis results
Traceability Look for the source of your analysis results Herman Ament, Cromsource CDISC UG Milan 21 October 2016 Contents Introduction, history and CDISC Traceability Examples Conclusion 2 / 24 Introduction,
More informationPharmaSUG DS05
PharmaSUG 2013 - DS05 Building Traceability for End Points in Datasets Using SRCDOM, SRCVAR, and SRCSEQ Triplet Xiangchen Cui, Vertex Pharmaceuticals Incorporated Tathabbai Pakalapati, Cytel Inc. Qunming
More informationXiangchen (Bob) Cui, Tathabbai Pakalapati, Qunming Dong Vertex Pharmaceuticals, Cambridge, MA
Building Traceability for End Points in Analysis Datasets Using SRCDOM, SRCVAR, and SRCSEQ Triplet Xiangchen (Bob) Cui, Tathabbai Pakalapati, Qunming Dong Vertex Pharmaceuticals, Cambridge, MA 2010 Vertex
More informationADaM and traceability: Chiesi experience
ADaM and traceability: Chiesi experience BIAS Seminar «Data handling and reporting in clinical trials with SAS» Glauco Cappellini 22-Feb-2013 Agenda Chiesi Model for Biometrics Regulatory Background ADaM:
More informationPharmaSUG Paper PO22
PharmaSUG 2015 - Paper PO22 Challenges in Developing ADSL with Baseline Data Hongyu Liu, Vertex Pharmaceuticals Incorporated, Boston, MA Hang Pang, Vertex Pharmaceuticals Incorporated, Boston, MA ABSTRACT
More informationADaM for Medical Devices: Extending the Current ADaM Structures
PharmaSUG 2018 - Paper MD-02 ADaM for Medical s: Extending the Current ADaM Structures Sandra Minjoe, PRA Health Sciences; Julia Yang, Medtronic PLC; Priya Gopal, TESARO, Inc. ABSTRACT The current ADaM
More informationA Taste of SDTM in Real Time
A Taste of SDTM in Real Time Changhong Shi, Merck & Co., Inc., Rahway, NJ Beilei Xu, Merck & Co., Inc., Rahway, NJ ABSTRACT The Study Data Tabulation Model (SDTM) is a Clinical Data Interchange Standards
More informationHow Macro Design and Program Structure Impacts GPP (Good Programming Practice) in TLF Coding
How Macro Design and Program Structure Impacts GPP (Good Programming Practice) in TLF Coding Galyna Repetatska, Kyiv, Ukraine PhUSE 2016, Barcelona Agenda Number of operations for SAS processor: between
More informationInterpreting CDISC ADaM IG through Users Interpretation
Paper CD01 Interpreting CDISC ADaM IG through Users Interpretation Angelo Tinazzi, Cytel Inc., Geneva, Switzerland ABSTRACT It is now almost three years CDISC ADaM is an official standard the pharmaceutical
More informationMaterial covered in the Dec 2014 FDA Binding Guidances
Accenture Accelerated R&D Services Rethink Reshape Restructure for better patient outcomes Sandra Minjoe Senior ADaM Consultant Preparing ADaM and Related Files for Submission Presentation Focus Material
More informationAn Introduction to Visit Window Challenges and Solutions
ABSTRACT Paper 125-2017 An Introduction to Visit Window Challenges and Solutions Mai Ngo, SynteractHCR In clinical trial studies, statistical programmers often face the challenge of subjects visits not
More informationAutomate Analysis Results Metadata in the Define-XML v2.0. Hong Qi, Majdoub Haloui, Larry Wu, Gregory T Golm Merck & Co., Inc.
Automate Analysis Results Metadata in the Define-XML v2.0 Hong Qi, Majdoub Haloui, Larry Wu, Gregory T Golm Merck & Co., Inc., USA 1 Topics Introduction Analysis Results Metadata (ARM) Version 1.0 o o
More informationThe Benefits of Traceability Beyond Just From SDTM to ADaM in CDISC Standards Maggie Ci Jiang, Teva Pharmaceuticals, Great Valley, PA
PharmaSUG 2017 - Paper DS23 The Benefits of Traceability Beyond Just From SDTM to ADaM in CDISC Standards Maggie Ci Jiang, Teva Pharmaceuticals, Great Valley, PA ABSTRACT Since FDA released the Analysis
More informationABSTRACT INTRODUCTION WHERE TO START? 1. DATA CHECK FOR CONSISTENCIES
Developing Integrated Summary of Safety Database using CDISC Standards Rajkumar Sharma, Genentech Inc., A member of the Roche Group, South San Francisco, CA ABSTRACT Most individual trials are not powered
More informationTHE DATA DETECTIVE HINTS AND TIPS FOR INDEPENDENT PROGRAMMING QC. PhUSE Bethan Thomas DATE PRESENTED BY
THE DATA DETECTIVE HINTS AND TIPS FOR INDEPENDENT PROGRAMMING QC DATE PhUSE 2016 PRESENTED BY Bethan Thomas What this presentation will cover And what this presentation will not cover What is a data detective?
More informationHarmonizing CDISC Data Standards across Companies: A Practical Overview with Examples
PharmaSUG 2017 - Paper DS06 Harmonizing CDISC Data Standards across Companies: A Practical Overview with Examples Keith Shusterman, Chiltern; Prathima Surabhi, AstraZeneca; Binoy Varghese, Medimmune ABSTRACT
More informationSandra Minjoe, Accenture Life Sciences John Brega, PharmaStat. PharmaSUG Single Day Event San Francisco Bay Area
Sandra Minjoe, Accenture Life Sciences John Brega, PharmaStat PharmaSUG Single Day Event San Francisco Bay Area 2015-02-10 What is the Computational Sciences Symposium? CSS originally formed to help FDA
More informationAUTOMATED CREATION OF SUBMISSION-READY ARTIFACTS SILAS MCKEE
AUTOMATED CREATION OF SUBMISSION-READY ARTIFACTS SILAS MCKEE AGENDA 1. Motivation 2. Automation Overview 3. Architecture 4. Validating the System 5. Pilot Study Results 6. Future State Copyright 2012-2017
More informationSorting big datasets. Do we really need it? Daniil Shliakhov, Experis Clinical, Kharkiv, Ukraine
PharmaSUG 2015 - Paper QT21 Sorting big datasets. Do we really need it? Daniil Shliakhov, Experis Clinical, Kharkiv, Ukraine ABSTRACT Very often working with big data causes difficulties for SAS programmers.
More informationSDTM-ETL 3.2 User Manual and Tutorial
SDTM-ETL 3.2 User Manual and Tutorial Author: Jozef Aerts, XML4Pharma Last update: 2017-07-29 Adding mappings for the Vital Signs domain After loading and validating the ODM file with metadata, your load
More informationUse of Traceability Chains in Study Data and Metadata for Regulatory Electronic Submission
PharmaSUG 2017 - Paper SS03 Use of Traceability Chains in Study Data and Metadata for Regulatory Electronic Submission ABSTRACT Tianshu Li, Celldex Therapeutics, Hampton, NJ Traceability is one of the
More informationRobust approach to create Define.xml v2.0. Vineet Jain
Robust approach to create Define.xml v2.0 Vineet Jain DEFINE SYSTEM GOALS Generic Powerful Reliable Integrable Efficient Works across SDTM, ADaM & SEND Create define.xml, annotated CRF & define.pdf Create
More informationBeyond OpenCDISC: Using Define.xml Metadata to Ensure End-to-End Submission Integrity. John Brega Linda Collins PharmaStat LLC
Beyond OpenCDISC: Using Define.xml Metadata to Ensure End-to-End Submission Integrity John Brega Linda Collins PharmaStat LLC Topics Part 1: A Standard with Many Uses Status of the Define.xml Standard
More informationPaper FC02. SDTM, Plus or Minus. Barry R. Cohen, Octagon Research Solutions, Wayne, PA
Paper FC02 SDTM, Plus or Minus Barry R. Cohen, Octagon Research Solutions, Wayne, PA ABSTRACT The CDISC Study Data Tabulation Model (SDTM) has become the industry standard for the regulatory submission
More informationConversion of CDISC specifications to CDISC data specifications driven SAS programming for CDISC data mapping
PharmaSUG 2017 - Paper DA03 Conversion of CDISC specifications to CDISC data specifications driven SAS programming for CDISC data mapping Yurong Dai, Jiangang Jameson Cai, Eli Lilly and Company ABSTRACT
More informationCommon Programming Errors in CDISC Data
ABSTRACT PharmaSUG 2017 - Paper DS15 Common Programming Errors in CDISC Data Sergiy Sirichenko, Pinnacle 21 Data in standardized format is now a required part of regulatory submissions. CDISC standards
More informationUpdates on CDISC Standards Validation
Updates on CDISC Standards Validation NJ CDISC User Group September 19, 2013 Topics CDISC standards validation initiative FDA update on SEND checks OpenCDISC v1.4.1 release OpenCDISC plans 2 CDISC validation
More informationPharmaSUG2014 Paper DS09
PharmaSUG2014 Paper DS09 An ADaM Interim Dataset for Time-to-Event Analysis Needs Tom Santopoli, Accenture, Berwyn, PA Kim Minkalis, Accenture, Berwyn, PA Sandra Minjoe, Accenture, Berwyn, PA ABSTRACT
More informationPlanning to Pool SDTM by Creating and Maintaining a Sponsor-Specific Controlled Terminology Database
PharmaSUG 2017 - Paper DS13 Planning to Pool SDTM by Creating and Maintaining a Sponsor-Specific Controlled Terminology Database ABSTRACT Cori Kramer, Ragini Hari, Keith Shusterman, Chiltern When SDTM
More informationValidating Analysis Data Set without Double Programming - An Alternative Way to Validate the Analysis Data Set
PharmaSUG 2014 Paper AD26 Validating Analysis Data Set without Double Programming - An Alternative Way to Validate the Analysis Data Set Linfeng Xu, Novartis, East Hanover, NJ Christina Scienski, Novartis,
More informationDefine.xml 2.0: More Functional, More Challenging
Define.xml 2.0: More Functional, More Challenging Bay Area CDISC Implementation Network 24 July 2013 John Brega, PharmaStat LLC Presentation Objectives 1. Introduce the new features in Define.xml 2.0 with
More informationImplementing CDISC Using SAS. Full book available for purchase here.
Implementing CDISC Using SAS. Full book available for purchase here. Contents About the Book... ix About the Authors... xv Chapter 1: Implementation Strategies... 1 The Case for Standards... 1 Which Models
More informationFrom Implementing CDISC Using SAS. Full book available for purchase here. About This Book... xi About The Authors... xvii Acknowledgments...
From Implementing CDISC Using SAS. Full book available for purchase here. Contents About This Book... xi About The Authors... xvii Acknowledgments... xix Chapter 1: Implementation Strategies... 1 Why CDISC
More informationSTART CONVERTING FROM TEXT DATE/TIME VALUES
A Macro Mapping Date and Time Variable to CDISC Date and Time Variable Song Liu, Biogen Idec, San Diego, California Brett Sellars, Biogen Idec, San Diego, California ABSTRACT The Clinical Data Interchange
More informationesubmission - Are you really Compliant?
ABSTRACT PharmaSUG 2018 - Paper SS21 esubmission - Are you really Compliant? Majdoub Haloui, Merck & Co., Inc., Upper Gwynedd, PA, USA Suhas R. Sanjee, Merck & Co., Inc., Upper Gwynedd, PA, USA Pinnacle
More informationIS03: An Introduction to SDTM Part II. Jennie Mc Guirk
IS03: An Introduction to SDTM Part II Jennie Mc Guirk SDTM Framework 1. Where should the data go? 3. What is the minimum information needed? 2. What type of information should it contain? SDTM Framework:
More informationAutomation of STDM dataset integration and ADaM dataset formation
PharmaSUG 2018 - Paper AD-32 Automation of STDM dataset integration and ADaM dataset formation William Wei, Merck & Co, Inc., Upper Gwynedd, PA, USA ABSTRACT Rinki Jajoo, Merck & Co, Inc., Rahway, NJ,
More informationLeveraging Study Data Reviewer s Guide (SDRG) in Building FDA s Confidence in Sponsor s Submitted Datasets
PharmaSUG 2017 - Paper SS09 Leveraging Study Data Reviewer s Guide (SDRG) in Building FDA s Confidence in Sponsor s Submitted Datasets Xiangchen (Bob) Cui, Min Chen, and Letan (Cleo) Lin, Alkermes Inc.,
More informationMaking a List, Checking it Twice (Part 1): Techniques for Specifying and Validating Analysis Datasets
PharmaSUG2011 Paper CD17 Making a List, Checking it Twice (Part 1): Techniques for Specifying and Validating Analysis Datasets Elizabeth Li, PharmaStat LLC, Newark, California Linda Collins, PharmaStat
More informationFrom Just Shells to a Detailed Specification Document for Tables, Listings and Figures Supriya Dalvi, InVentiv Health Clinical, Mumbai, India
PharmaSUG 2014 - Paper IB07 From Just Shells to a Detailed Specification Document for Tables, Listings and Figures Supriya Dalvi, InVentiv Health Clinical, Mumbai, India ABSTRACT We are assigned a new
More informationExperience of electronic data submission via Gateway to PMDA
PharmaSUG 2018 - Paper EP-21 ABSTRACT Experience of electronic data submission via Gateway to PMDA Iori Sakakibara, Kumiko Kimura, Amgen Astellas BioPharma K.K. and Laurence Carpenter, Amgen Ltd PMDA started
More informationReproducibly Random Values William Garner, Gilead Sciences, Inc., Foster City, CA Ting Bai, Gilead Sciences, Inc., Foster City, CA
ABSTRACT PharmaSUG 2015 - Paper QT24 Reproducibly Random Values William Garner, Gilead Sciences, Inc., Foster City, CA Ting Bai, Gilead Sciences, Inc., Foster City, CA For questionnaire data, multiple
More informationStudy Data Reviewer s Guide Completion Guideline
Study Data Reviewer s Guide Completion Guideline 22-Feb-2013 Revision History Date Version Summary 02-Nov-2012 0.1 Draft 20-Nov-2012 0.2 Added Finalization Instructions 10-Jan-2013 0.3 Updated based on
More informationConsiderations on creation of SDTM datasets for extended studies
13/May/2016 As one of the activities of CDISC Japan User Group (CJUG), a small group, "Extension study team" was organized in 2015. The team discussed what kind of approach works better for SDTM creation
More informationPharmaSUG Paper PO21
PharmaSUG 2015 - Paper PO21 Evaluating SDTM SUPP Domain For AdaM - Trash Can Or Buried Treasure Xiaopeng Li, Celerion, Lincoln, NE Yi Liu, Celerion, Lincoln, NE Chun Feng, Celerion, Lincoln, NE ABSTRACT
More informationPaper DS07. Generating Define.xml and Analysis Result Metadata using Specifications, Datasets and TFL Annotation
Paper DS07 Generating Define.xml and Analysis Result Metadata using Specifications, s and TFL Annotation Mark Crangle, ICON Clinical Research, Marlow, United Kingdom ABSTRACT The most recent addition to
More informationAdvanced Data Visualization using TIBCO Spotfire and SAS using SDTM. Ajay Gupta, PPD
Advanced Data Visualization using TIBCO Spotfire and SAS using SDTM Ajay Gupta, PPD INTRODUCTION + TIBCO Spotfire is an analytics and business intelligence platform, which enables data visualization in
More informationCustomer oriented CDISC implementation
Paper CD10 Customer oriented CDISC implementation Edelbert Arnold, Accovion GmbH, Eschborn, Germany Ulrike Plank, Accovion GmbH, Eschborn, Germany ABSTRACT The Clinical Data Interchange Standards Consortium
More informationMapping and Terminology. English Speaking CDISC User Group Meeting on 13-Mar-08
Mapping and Terminology English Speaking CDISC User Group Meeting on 13-Mar-08 Statement of the Problem GSK has a large drug portfolio, therefore there are many drug project teams GSK has standards 8,200
More informationPhUSE Paper TT05
Paper TT05 Generating Analysis Results and Metadata report from a PhUSE CS project Marc Andersen, StatGroup ApS, Copenhagen, Denmark Marcelina Hungria, DIcore Group, LLC, NJ, USA Suhas R. Sanjee, Merck
More informationHow Macro Design and Program Structure Impacts GPP (Good Programming Practice) in TLF Coding
Paper CC06 How Macro Design and Program Structure Impacts GPP (Good Programming Practice) in TLF Coding Galyna Repetatska, Chiltern, Kyiv, Ukraine ABSTRACT Good program structure and macro design are critical
More informationPharmaSUG China Paper 70
ABSTRACT PharmaSUG China 2015 - Paper 70 SAS Longitudinal Data Techniques - From Change from Baseline to Change from Previous Visits Chao Wang, Fountain Medical Development, Inc., Nanjing, China Longitudinal
More informationGlobal Checklist to QC SDTM Lab Data Murali Marneni, PPD, LLC, Morrisville, NC Sekhar Badam, PPD, LLC, Morrisville, NC
PharmaSUG 2018 Paper DS-13 Global Checklist to QC SDTM Lab Data Murali Marneni, PPD, LLC, Morrisville, NC Sekhar Badam, PPD, LLC, Morrisville, NC ABSTRACT Laboratory data is one of the primary datasets
More informationNow let s take a look
1 2 3 4 Manage assets across the end to end life cycle of your studies This includes forms, datasets, terminologies, files, links and more, for example: - Studies may contain the protocol, a set of Forms,
More informationPharmaSUG Paper CD16
PharmaSUG2010 - Paper CD16 Checking for SDTM Compliance: The Need for Human Involvement Fred Wood and Adrienne Boyance Data Standards Consulting Octagon Research Solutions, Wayne, PA ABSTRACT An increasing
More informationOptimization of the traceability when applying an ADaM Parallel Conversion Method
SI04 Optimization of the traceability when applying an ADaM Parallel Conversion Method Roxane Debrus ADaM Conversion Process Agenda %LIB_QC_contents_html %adam_sdtm_compa Conclusion ADaM Conversion Process
More informationThe application of SDTM in a disease (oncology)-oriented organization
Paper CD01 The application of SDTM in a disease (oncology)-oriented organization Angelo Tinazzi, Alessandro Cattaneo, Enrica Paschetto, Sonia Colombini SENDO-Tech S.r.l., Milan, Italy ABSTRACT Applying
More informationCDISC SDTM and ADaM Real World Issues
CDISC SDTM and ADaM Real World Issues Washington DC CDISC Data Standards User Group Meeting Sy Truong President MXI, Meta-Xceed, Inc. http://www.meta-x.com Agenda CDISC SDTM and ADaM Fundamentals CDISC
More informationAZ CDISC Implementation
AZ CDISC Implementation A brief history of CDISC implementation Stephen Harrison Overview Background CDISC Implementation Strategy First steps Business as usual ADaM or RDB? Lessons learned Summary 2 Background
More informationAutomated generation of program templates with metadata based specification documents for integrated analysis Thomas Wollseifen, Germany Vienna, Oct
Automated generation of program templates with metadata based specification documents for integrated analysis Thomas Wollseifen, Germany Vienna, Oct 2015 Content 1. Introduction to data integration process
More informationDIA 11234: CDER Data Standards Common Issues Document webinar questions
Q: What is the preferred data definition format for ADaM analysis data, define.xml or define.pdf? 1 ADaM Define File Q: The CRTDDS does not describe how to submit a define.xml for ADaM. Does CDER expect
More informationSTUDY DATA TECHNICAL CONFORMANCE GUIDE
STUDY DATA TECHNICAL CONFORMANCE GUIDE Technical Specifications Document This Document is incorporated by reference into the following Guidance Document(s): Guidance for Industry Providing Regulatory Submissions
More informationStandardising The Standards The Benefits of Consistency
Paper DH06 Standardising The Standards The Benefits of Consistency Nathan James, Roche Products Ltd., Welwyn Garden City, UK ABSTRACT The introduction of the Study Data Tabulation Model (SDTM) has had
More informationDoctor's Prescription to Re-engineer Process of Pinnacle 21 Community Version Friendly ADaM Development
PharmaSUG 2018 - Paper DS-15 Doctor's Prescription to Re-engineer Process of Pinnacle 21 Community Version Friendly ADaM Development Aakar Shah, Pfizer Inc; Tracy Sherman, Ephicacy Consulting Group, Inc.
More informationWorking with Composite Endpoints: Constructing Analysis Data Pushpa Saranadasa, Merck & Co., Inc., Upper Gwynedd, PA
PharmaSug2016- Paper HA03 Working with Composite Endpoints: Constructing Analysis Data Pushpa Saranadasa, Merck & Co., Inc., Upper Gwynedd, PA ABSTRACT A composite endpoint in a Randomized Clinical Trial
More information